JP Morgan Chase Portfolio holdings
JPMorgan Chase & Co., formed by the 2000 merger of J.P. Morgan & Co. and Chase Manhattan Bank, is a global financial services giant headquartered in New York City, tracing its roots back to 1799 through its predecessor firms. As one of the largest banks in the world, it operates across investment banking, commercial banking, asset management, and consumer banking, managing trillions in assets and serving millions of customers, corporations, and governments. Led by CEO Jamie Dimon since 2005, the firm is renowned for its role in high-profile deals, robust trading operations, and its Chase retail banking network, which includes extensive credit card and mortgage services. Combining a legacy of financial innovation with a dominant market presence, JPMorgan Chase remains a cornerstone of the global economy.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Broadcom
AVGO
|
+$3.21B |
| 2 |
Arthur J. Gallagher & Co
AJG
|
+$2.24B |
| 3 |
Walt Disney
DIS
|
+$2.18B |
| 4 |
Walmart Inc
WMT
|
+$1.96B |
| 5 |
McDonald's
MCD
|
+$1.91B |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Eli Lilly
LLY
|
+$2.77B |
| 2 |
JPMorgan BetaBuilders Europe ETF
BBEU
|
+$2.64B |
| 3 |
Vanguard Long-Term Treasury ETF
VGLT
|
+$2.5B |
| 4 |
iShares Broad USD High Yield Corporate Bond ETF
USHY
|
+$2.23B |
| 5 |
State Street SPDR S&P 500 ETF Trust
SPY
|
+$2.06B |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Miscellaneous | 24.61% |
| 2 | Technology | 23.17% |
| 3 | Financials | 10.12% |
| 4 | Consumer Discretionary | 9.84% |
| 5 | Healthcare | 7.97% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
3851
CALL
PTC Therapeutics
PTCT
$5.3B
| $2.44M | ﹤0.01% |
+54,000
| New | +$2.31M |
2024 Q4
0 quarters
|
|
|
3852
PUT
PTC Therapeutics
PTCT
$5.3B
| $2.44M | ﹤0.01% |
+54,000
| New | +$2.31M |
2024 Q4
0 quarters
|
|
|
ARES.PRB
3853
Ares Management Corp 6.75% Series B Preferred Stock
ARES.PRB
$1.16B
| $2.44M | ﹤0.01% |
+44,269
| New | +$2.44M |
2024 Q4
0 quarters
|
|
3854
Plug Power
PLUG
$2.65B
| $2.43M | ﹤0.01% |
1,143,179
+32,915
| +3% | +$71.8K |
2017 Q3
29 quarters
|
|
|
RDUS
3855
DELISTED
Radius Recycling
RDUS
| $2.43M | ﹤0.01% |
159,621
+76,702
| +93% | +$1.38M |
2013 Q2
46 quarters
|
|
3856
Schrodinger
SDGR
$2.27B
| $2.42M | ﹤0.01% |
125,479
+2,777
| +2% | +$53.9K |
2020 Q1
19 quarters
|
|
3857
Honda
HMC
$40.7B
| $2.42M | ﹤0.01% |
84,656
+26,917
| +47% | +$761K |
2013 Q2
46 quarters
|
|
3858
Cullinan Oncology
CGEM
$998M
| $2.41M | ﹤0.01% |
198,214
+169,104
| +581% | +$2.43M |
2021 Q1
15 quarters
|
|
3859
Invesco S&P 500 Pure Value ETF
RPV
$1.66B
| $2.41M | ﹤0.01% |
26,751
+23,846
| +821% | +$2.19M |
2013 Q2
46 quarters
|
|
|
ETNB
3860
DELISTED
89bio
ETNB
| $2.41M | ﹤0.01% |
308,459
+208,992
| +210% | +$1.72M |
2019 Q4
20 quarters
|
|
3861
Vanguard Russell 2000 Growth ETF
VTWG
$1.44B
| $2.41M | ﹤0.01% |
11,477
+2,424
| +27% | +$523K |
2021 Q1
15 quarters
|
|
3862
CALL
Philip Morris
PM
$292B
| $2.41M | ﹤0.01% |
+20,000
| New | +$2.52M |
2024 Q4
0 quarters
|
|
3863
iShares ESG Aware MSCI USA Small-Cap ETF
ESML
$2.78B
| $2.4M | ﹤0.01% |
57,127
+11,294
| +25% | +$488K |
2022 Q4
8 quarters
|
|
3864
TechTarget
TTGT
$258M
| $2.4M | ﹤0.01% |
121,155
+90,314
| +293% | +$2.38M |
2016 Q2
34 quarters
|
|
|
JMIA
3865
Jumia Technologies
JMIA
$925M
| $2.39M | ﹤0.01% |
626,945
-103,245
| -14% | -$463K |
2020 Q2
18 quarters
|
|
3866
Nuveen Enhanced Yield US Aggregate Bond ETF
NUAG
$105M
| $2.39M | ﹤0.01% |
116,020
+115,953
| +173,064% | +$2.44M |
2024 Q3
1 quarter
|
|
3867
CALL
CME Group
CME
$94.6B
| $2.39M | ﹤0.01% |
10,300
-52,500
| -84% | -$12.1M |
2021 Q1
15 quarters
|
|
|
AMTM
3868
Amentum Holdings
AMTM
$4.44B
| $2.39M | ﹤0.01% |
113,674
-157,295
| -58% | -$4.07M |
2024 Q3
1 quarter
|
|
3869
BOK Financial
BOKF
$7.8B
| $2.39M | ﹤0.01% |
22,434
+961
| +4% | +$107K |
2019 Q2
22 quarters
|
|
3870
PUT
Neumora Therapeutics
NMRA
$93.9M
| $2.38M | ﹤0.01% |
+225,000
| New | +$2.7M |
2024 Q4
0 quarters
|
|
3871
iShares iBonds Dec 2027 Term Corporate ETF
IBDS
$3.9B
| $2.38M | ﹤0.01% |
99,439
+10,632
| +12% | +$256K |
2022 Q2
10 quarters
|
|
3872
Graham Corp
GHM
$1.07B
| $2.38M | ﹤0.01% |
53,506
+14,526
| +37% | +$544K |
2015 Q4
36 quarters
|
|
3873
CALL
CoStar Group
CSGP
$11.1B
| $2.37M | ﹤0.01% |
+33,100
| New | +$2.5M |
2024 Q4
0 quarters
|
|
3874
Collegium Pharmaceutical
COLL
$717M
| $2.37M | ﹤0.01% |
82,691
-194,513
| -70% | -$6.44M |
2017 Q3
29 quarters
|
|
3875
CALL
Centene
CNC
$31.1B
| $2.36M | ﹤0.01% |
39,000
-4,200
| -10% | -$262K |
2024 Q3
1 quarter
|
|
Similar funds
JP Morgan Chase's Q4 2024 Portfolio in Review
As of Q4 2024, JP Morgan Chase held 7,917 positions worth $1.34T, up 2.1% from $1.32T the previous quarter. Its ten largest holdings account for 24% of the portfolio.
JP Morgan Chase's Q4 2024 filing shows 509 new, 3,351 increased, 2,465 reduced and 522 closed positions. Its largest new stake was Primo Brands: 3,989,501 shares worth $123M. The largest sale was Eli Lilly, an estimated $2.77B.
By sector, the portfolio is most concentrated in Miscellaneous at 25% of assets, up from 24% a quarter earlier, followed by Technology and Financials.
- JP Morgan Chase's largest Q4 2024 buy was Primo Brands: 3,989,501 shares worth $123M.
- JP Morgan Chase added most to Broadcom in Q4 2024, an estimated $3.21B increase.
- JP Morgan Chase's biggest Q4 2024 reduction was Eli Lilly, cutting an estimated $2.77B.
- JP Morgan Chase fully exited Stericycle Inc in Q4 2024, selling an estimated $183M.
- JP Morgan Chase's ten largest holdings make up 24% of its $1.34T portfolio in Q4 2024.
- JP Morgan Chase opened 509 new positions and closed 522 in Q4 2024.
- JP Morgan Chase's portfolio value rose 2.1% quarter-over-quarter to $1.34T.
Based on JP Morgan Chase's 13F filing for Q4 2024, filed 12 Feb 2025.